NewsNew UK Company Heralds Its ‘Unique’ Medical Cannabis Delivery...

New UK Company Heralds Its ‘Unique’ Medical Cannabis Delivery Mechanism


CANNABIS extraction and formulations specialist 113 Botanicals is in the process of securing Good manufacturing Practice (GMP) compliance for its newly-acquired 7,500sq ft production facility in Sussex, UK.

This facility will be be used to manufacture its patented, capsule-technology, cannabis products for sale into the UK, European and then global markets.

The company anticipates GMP compliance to be in place by the end of the year, and, after in-depth discussions with the UK Medicines and Healthcare Products Regulatory Agency (MHRA), is confident of securing its first commercial sales in Q3 2023.

This planned commercial debut will come four years after the company’s launch – a period during which it has developed and patented a range of sustained-release, controlled-dosage cannabis capsules in partnership with the School of Life Sciences, at the University of Sussex.

Sustained Release; Controlled Dose

Co Founder and COO Kate Cook, told BusinessCann: “Following MHRA approval our aim is to enter the cannabis Specials market in Q3 2023.

“This will include the UK, Europe – in particular Germany, with it being an already very-well established Specials market –  and additionally Australia and Israel. Further international expansion is planned from Q1 2024.”

113 Botanicals is led by Chief Technical Officer Mazin Nicola, who is based at the University of Sussex.

Mazin Nicola

It is here on the south coast of England that it has developed an oral cannabis capsule formulation which it believes surpasses in effectiveness more commonly used cannabis delivery mechanisms, namely; smoking and vaping flower, or other sub-lingual formulations. 

Ms Cook explained: “Our sustained-release, controlled-dose capsules are designed to bypasses the stomach and to release directly into the pulmonary system via the hilum.

“They represent a uniquely effective new route of administration for cannabis derived medicines offering continuous supply of medicine over an eight-hour time period, eliminating the need for multi-dosing.”

To date 113 has invested over £1m – including £0.76m which has been successfully SEIS/EIS approved, and it is now looking to raise a further £5m to take it through to commercial production and revenue generation.

Clever Leaves And Bedrocan

The company works closely with its biomass supplier Clever Leaves and has developed close research ties with leading Dutch cannabis firm Bedrocan.

113 is looking beyond the initial debut in the Specials market with a focus on the pharmaceutical market. This will be supported with the launch of a pre-clinical trials programme in Q1 2024 in preparation for clinical trials in late 2024. 

Ms Cook added: “We have already established, through discussions with the Innovation Centre, University of Sussex, that when appropriate for us to embark on Phase2 clinical trials programme, we can anticipate active support from various departments including: the Sussex Drug Discovery Centre, the School of Life Sciences, School of Medicine, Chemistry Department, Pharmaceutics Science Department and the Sussex Clinical Imaging Sciences Centre.

“With the current pharmaceutical market for CBPMs dominated by Sativex, Epidiolex and dronabinol, we would be offering our alternative product with its innovative route of administration, provided by our sustained-release, controlled-dosage capsules – a format that we feel medical practitioners would be more confident prescribing.”

113 Botanicals will produce six formulations featuring various CBD to THC ratios with these based on its own full-spectrum API, produced with its bespoke and patented extraction technology.

As well as Ms Cook and Mr Nicola the co-founders include pharmaceutical expert Tim Kneen, as Non-Executive Director, CFO Simon Price; a former Merrill Lynch investment banker and CEO Leslie Maguire.

Main image : University of Sussex Life Science Building

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

Tilray’s Medical Cannabis Product Now Available And Reimbursed Under Ireland’s Medical Cannabis Access Program

PRESS RELEASE TILRAY Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and...

Grow Group, Kanabo, MGC Pharma & Celadon Pharma All Report Growing Revenues, But Continue To Post Losses

AMID the economic chaos that dominated the headlines over the past week, nearly half-a-dozen UK-based or UK-listed cannabis companies...

MGC Pharma Announces Appointment Of UK Advisor And New COO/Deputy CEO

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based bio-pharma company specialising in the production and development...

Sanity Group’s Record Funding Round Led By BAT Could Bring More Big-Tobacco Capital To Cannabis, But Concerns Remain Over Conflicts Of Interest

LAST week Berlin-based cannabis operator Sanity Group closed Europe’s largest ever cannabis investment round worth €37.6m, bringing its total...

European Cannabis Stocks Review: £22m Wiped From LSE-Listed Cannabis Stocks Amid Market Chaos

FOLLOWING a few weeks of relative positivity for many of the stocks listed on the London Stock Exchange (LSE),...

German SPD Representatives Confident A Solution To International Legal Hurdles Will Be Found

EARLIER this month news broke that recent analysis conducted by the Bundestag's scientific service suggested the creation of a...

Must read

You might also likeRELATED
Recommended to you